Navigation Links
Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
Date:5/18/2012

ct introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:Steven Campanini508-652-5740 (office)Media RelationsBoston Scientific Corporationsteven.campanini@bsci.comSean Findlen617-520-7268 (office)Media RelationsWeber Shandwicksfindlen@webershandwick.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com 


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
2. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
3. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
4. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
5. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
6. Medical Device Developers - Network at BIOMEDevice Boston Next Week
7. Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27
8. Boston Scientific Launches Innovative Device Used to Prevent Stone Migration in Urologic Procedures
9. Annual Biotech and Healthcare Conferences Being Held in Boston MA, Summer 2012
10. Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... HAYWARD, Calif. , July 6, 2015  Impax ... Larry Hsu , Ph.D. has resigned from the ... business activities. Dr. Hsu was a co-founder of Impax ... Chief Executive Officer from October 2006 until April 2014. ... Fred Wilkinson , Impax,s President and Chief Executive ...
(Date:7/6/2015)... , July 6, 2015 Akcea Therapeutics, ... ISIS ), announced today that the U.S. ... Designation to volanesorsen (ISIS-APOCIII Rx ) for the ... FCS is a rare genetic disease characterized by ... In a Phase 2 study published in the ...
(Date:7/6/2015)... , July 6, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore ... a leading retail drugstore chain in China ... stores, today announced that its board of directors has ... 2015, from Simin Zhang , chairman of the ... Drugstore Holding Ltd., an investment vehicle wholly owned by ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Scientific Pte. Ltd today announced that the National University ... in its groundbreaking study: Abdominal Wall Closure After ... of TIGR® Matrix (100% Resorbable) ... received DSRB approval on 9th September 2010. There are ...
... PennDOT and the Pennsylvania State Police are reminding motorists ... over-the-counter medication can be just as dangerous as driving ... PennDOT will work with state and municipal ... enforcement, with increased emphasis on driving under the influence ...
Cached Medicine Technology:National University Hospital Singapore Operates on Asia's 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Mesh 2National University Hospital Singapore Operates on Asia's 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Mesh 3PennDOT, State Police Caution Motorists About Dangers of Driving Under Influence of Legal Drugs 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... Medical Spa industries, announces the return of its complimentary educational webinar series ... aesthetic medical business leaders creates success for their clients through targeted marketing, sales, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ranks ... a particular demographic, however, fat reduction has become more than a way to ...
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... doTERRA, the ... to its executive management team. Most recently, Jowers held the position as Director of ... years. , After spending a decade building the institute, Jowers states that he was ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... AGA Medical Corporation ("AGA,Medical") announced today that it ... and Welfare (MHLW) for its AMPLATZER(R) Duct Occluder ... used for the,non-surgical closure of patent ductus arteriosus ... occurs when a blood vessel known as the ...
... Medical Innovations, Inc. (NYSE: IMA ), a ... solutions, has introduced the pima(TM) analyzer, a ... The initial application of the instrument will be a ... instrument is one of several novel technologies under development ...
... national health care reform a top priority of the ... proposals swirling about Washington, D.C., and around the country, ... stepping up its efforts to identify and launch new ... care delivery systems.With health care reform a central feature ...
... awareness and knowledge of Daiichi Sankyo,s innovative treatmentsPARSIPPANY, N.J., ... it has established a subsidiary -- Daiichi Sankyo de ... Inc. is based in San Juan, and led by ... more than 20 years of experience in pharmaceutical sales ...
... FDA-approved once-daily amoxicillin will be promoted to health ... Pharmaceuticals, Inc. (Nasdaq: MBRK ), today ... extended-release) Tablets, 775mg, will begin on March 16, ... of its 270-person field force which will promote ...
... - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... identified a cosmetics company as a potential merger candidate. ... is engaged in online sales of the "Melem" product. ... It has a wide variety of skin and lip ...
Cached Medicine News:Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 2Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 3Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 2Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 3Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 2Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 3Health News:Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 3Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 4Health News:Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company 2
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: